As expected, naxitamab exhibits modest toxic effects, low immunogenicity, and substantial anti-neuroblastoma activity in combination with GM-CSF in patients with relapsed or refractory high-risk neuroblastoma [756–758] (Fig. 9j). This evidence concerns the gene CSF2 and neuroblastoma.